See feature articles below:

 

About Broad Street Alerts:

Big opportunities in Small Cap’s

 

Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our members on the last 3 small cap alerts alone!

 

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%

 

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

 

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.

 

These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

 

Report For: CTIX

 

BEVERLY, MA–(Marketwired – March 01, 2016) – Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that dosing has been completed in the Company’s Phase 2 trial of Prurisol for the treatment of mild to moderate chronic plaque psoriasis. Approximately 7.5 million people in the U.S. are diagnosed with some form of psoriasis, a chronic immune-mediated skin disorder presenting with varying symptoms and levels of severity.

Based on compelling pre-clinical data, Cellceutix purposely set the bar high for the Phase 2 trial by targeting mild to moderate plaque psoriasis with an oral drug. By doing this, the Company is assessing Prurisol potentially for two different and very large markets in the psoriasis space. First, there are currently limited oral medications for mild to moderate chronic plaque psoriasis. Second, there is a need for new non-biologic oral treatments for moderate to severe chronic plaque psoriasis. Various trial endpoints will be studied once the trial is completed.

In the Phase 2 trial, physicians selected and evaluated a specific lesion while the patient was treated with a Prurisol or placebo tablet, as opposed to treating the lesion with a cream or gel, a common method used in clinical trials for the treatment of mild to moderate chronic plaque psoriasis.

“As the trial is a randomized, double-blind design with a placebo arm, we, nor anyone, can speculate on the outcome until all data is collected, un-blinded and analyzed.” commented Leo Ehrlich, Chief Executive Officer at Cellceutix. ”Should the trial be a success, our plan is to seek a partnership through discussions with parties that have previously shown interest in Prurisol.”

Cellceutix is developing Prurisol under the U.S. Food and Drug Administration’s 505(b)(2) pathway, which can help expedite a drug’s approval by relying, in part, on clinical data from an already approved drug.

The randomized, double-blind Phase 2 trial for chronic psoriasis is designed to evaluate the safety and efficacy of Prurisol as compared to a placebo. In a four-arm, multi-center trial, three arms of the study were administered different dosing regimens of oral Prurisol and one arm was administered an oral placebo for a period of 84 days. The subjects will now be followed for an additional 28 days without taking additional study medication. The final study visit and data collection for the last subject is expected to be completed by early April 2016, with top-line data made available approximately four weeks later. The primary endpoint to be evaluated is the percentage of subjects with greater than or equal to a 2-point improvement in Investigator’s Global Assessment (IGA) rating as defined by visual inspections of patient’s target lesion.

 

 

 

 

 

Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.

 

 

Stock market

 

Hot small cap stocks

 

small cap stock picks

 

Biotech stocks

 

FDA approval stocks

 

FDA calendar

 

Trade stocks

 

Become a day trader

 

Day trade stocks for a living

 

PDUFA date set

 

micro cap stocks

 

Best stocks 2016

 

Hottest small cap stocks

 

Best stock picks

 

Who to follow for stock picks

 

Apple news stock picks

 

Stock picks on apple news

See feature articles below:

 

About Broad Street Alerts:

Big opportunities in Small Cap’s

 

Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our members on the last 3 small cap alerts alone!

 

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%

 

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

 

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.

 

These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

 

Report for: TRVN

Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), today announced financial results for the fourth quarter and full year ended December 31, 2015 and provided an update regarding its ongoing clinical programs.

“In 2015, we made remarkable progress in building the company and advancing our pipeline,” said Maxine Gowen, Ph.D., chief executive officer. “Our Phase 2b data for intravenous oliceridine in moderate-to-severe post-operative pain demonstrated impressive results compared to morphine and concluded a Phase 2 program that supported a Breakthrough Therapy designation from the FDA. We also added key personnel and expertise to the company and are well positioned to advance oliceridine through Phase 3, an NDA filing, and towards commercial launch.  In addition, we significantly progressed the ongoing TRV027 Phase 2 study and our earlier programs, and strengthened our balance sheet to enable furtherance of these important programs.”

2015 and Recent Corporate Highlights

CNS Programs (oliceridine, TRV734, and TRV250)

Announced positive results from Phase 2b study of oliceridine (TRV130).  In August, the company announced positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of oliceridine in moderate to severe acute pain after abdominoplasty surgery.  The study achieved its primary endpoint of statistically greater pain reduction than placebo over 24 hours.  In addition, in pre-specified secondary measures, oliceridine demonstrated significantly reduced nausea, vomiting, and hypoventilation events with similar levels of analgesia compared to morphine.

Initiated the Phase 3 program for oliceridine.  In January 2016, the company announced the launch of the oliceridine Phase 3 clinical program with the enrollment of patients in the open-label Phase 3 ATHENA-1 study.  This study will evaluate the safety and tolerability of oliceridine in patients with acute moderate-to-severe pain in a variety of surgical and medical settings.

Received Breakthrough Therapy designation for oliceridine.  In February 2016, the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to the Company’s lead product candidate, intravenous oliceridine, for the management of moderate-to-severe acute pain.  Based on publicly available information, the company believes that this is the first and only Breakthrough Therapy designation granted to a product candidate for the treatment of pain.  Breakthrough Therapy designation is granted by the FDA to new therapies intended to treat serious conditions, and for which preliminary clinical evidence indicates that the drug may demonstrate substantial clinical improvement over available therapies.

Presented oliceridine Phase 2 data in peer-reviewed forums.  In September, complete results from the company’s Phase 2 bunionectomy study of oliceridine were published in the leading journal PAIN.  In addition, in September, the company highlighted data from this study, as well as data from its other CNS programs, at PAINWeek®, the National Conference on Pain for Frontline Practitioners.

Reported positive phase 1 data for TRV734.  In September and February 2015, Trevena reported data from two Phase 1 studies of TRV734, an orally administered clinical compound expected to be used for first-line treatment of moderate to severe acute and chronic pain.  Results showed pharmacokinetics, safety, tolerability, and CNS activity supporting further study in Phase 2. The company has now completed the Phase 1 program for TRV734, and intends to continue to focus its efforts on securing a worldwide development and commercialization partner for this compound.

Advanced TRV250, a G protein biased ligand targeting the delta receptor, into preclinical development.  TRV250 is a potential first-in-class treatment for acute intermittent migraine that also may have utility in a range of other central nervous system indications.  There are no approved drugs selectively targeting the delta receptor.  The company currently expects to submit an investigational new drug application for TRV250 to the FDA in the second half of 2016.

Presented TRV250 preclinical data.  In May and June, Trevena presented the preclinical pharmacology of TRV250 in a late-breaking oral session at the International Headache Society meeting in Valencia, Spain, and in a poster at the American Headache Society 57^thannual meeting in Washington, D.C., respectively.

Acute Heart Failure Program (TRV027)

Expanded TRV027 Phase 2b BLAST-AHF trial and completed enrollment. Early last year, the company conducted a planned interim analysis evaluating data from approximately 250 patients. Upon reviewing the data, the data safety monitoring board and the BLAST‑AHF Steering Committee recommended that future enrollment be weighted to the most promising dose of 5 mg/hr. The company announced in March 2015 that remaining enrollment will be weighted 2:1:2:1 for placebo, 1 mg/hr, 5 mg/hr, and 25 mg/hr, respectively, and that target enrollment in the study had been increased from 500 patients to 620 patients. Allergan plc, which holds an exclusive option to license TRV027, made a $10 million payment to Trevena to fully fund the external and internal costs of increasing the study sample size. Enrollment in the BLAST-AHF study has now concluded.  Following scheduled 30 day measures and data collection and database lock, the company expects to release top line data in the second quarter of 2016.

Published the TRV027 Phase 2b BLAST-AHF trial design.  In February 2015, the company announced the publication of the trial design for its ongoing Phase 2b study of TRV027 in acute heart failure in the Journal of the American College of Cardiology: Heart Failure.

Received key U.S. and EU patents for TRV027.  In August, the company announced that the U.S. Patent and Trademark Office granted Trevena U.S. Patent No. 8,796,204, a new patent covering methods of use for TRV027 for the treatment of cardiovascular disorders, including acute heart failure. The patent is expected to provide coverage for TRV027 until at least 2029, strengthening the protection provided by the previously issued composition of matter patent which is expected to extend until at least 2031.  In December, the company announced that the European Patent Office has granted European Patent EP2376101B1, “Beta-Arrestin Effectors and Compositions and Methods of Use Thereof,” which covers the composition of matter for TRV027 and uses thereof.

Corporate Developments

Strengthened corporate management team.  Trevena added two new executives to the management team. In May, the company appointed Carrie Bourdow as chief commercial officer and, in July, Yacoub Habib Ph.D. was appointed senior vice president, business development and corporate planning.

Hosted first Investor and Analyst Day.  Leading external researchers and Trevena management discussed the Phase 3 and commercial plans for oliceridine and the rationale for and design of the ongoing Phase 2b study of TRV027 during an Investor and Analyst Day in October.

Financial Results

For the fourth quarter of 2015, Trevena reported a net loss attributable to common stockholders of $15.5 million, or $0.30 per share, compared with a net loss attributable to common stockholders for the fourth quarter of 2014 of $13.3 million, or $0.45 per share.

For the year ended December 31, 2015, the company incurred a net loss attributable to common stockholders of $50.5 million, or $1.15 per share, compared with a net loss attributable to common stockholders of $49.7 million, or $2.02 per share, for the comparable period in 2014.

Cash, cash equivalents and marketable securities were $172.6 million as of December 31, 2015, which the company expects to fund operations into 2018, including completion of oliceridine Phase 3 studies, NDA filing in the second half of 2017, and commercial launch preparations, as well as funding the continued progress of Trevena’s pipeline.

Source – Company Press Release

 

 

 

Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.

 

 

Stock market

 

Hot small cap stocks

 

small cap stock picks

 

Biotech stocks

 

FDA approval stocks

 

FDA calendar

 

Trade stocks

 

Become a day trader

 

Day trade stocks for a living

 

PDUFA date set

 

micro cap stocks

 

Best stocks 2016

 

Hottest small cap stocks

 

Best stock picks

 

Who to follow for stock picks

 

Apple news stock picks

 

Stock picks on apple news

 
See feature articles below: (NASDAQ:EBIO)

About Broad Street Alerts:
Big opportunities in Small Cap’s

Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
–Report on: (NASDAQ:EBIO)
Trade-Ideas LLC identified Eleven Biotherapeutics ( EBIO) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Eleven Biotherapeutics as such a stock due to the following factors:
EBIO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $7.5 million.
EBIO has traded 5.1 million shares today.
EBIO is trading at 42.18 times the normal volume for the stock at this time of day.
EBIO is trading at a new high 43.14% above yesterday’s close.

‘Strong on High Relative Volume’ stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from ‘superinvestors,’ or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

Eleven BiotherapeuticsInc (EBIO) on April 29, 2016announced that one oral presentation and three posters have been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting taking place May 1-5, 2016, in Seattle, WA. The presentations include preclinical data for EBI-031, which is in development for diabetic macular edema and Phase 3 clinical data on isunakinra (EBI-005). Presentation abstracts can be found on the ARVO website at https://www.arvo.org/AM/Program/.

Eleven Biotherapeutics’ most advanced preclinical product candidate is EBI-031 for treatment of diabetic macular edema, or DME, and uveitis. EBI-031 was designed and engineered for intravitreal delivery using Eleven’s AMP-Rx platform. EBI-031 is a potent blocker of both free IL-6 and IL-6 complexed to the soluble IL-6 receptor (IL-6R) and has demonstrated a longer vitreal retention time in preclinical models than antibodies and antibody like molecules approved for intravitreal injection. Eleven is undertaking the necessary manufacturing development work and nonclinical safety studies to support the submission of an investigational new drug application, or IND, to the FDA in the first half of 2016 for the purpose of conducting clinical trials of EBI-031 in DME and uveitis.

A price target is a projected price level as stated by an investment analyst or advisor.
A Number of brokers believe that the price target for the company may go as high as $12.00 whereas, the low target suggested by the brokers is $12.00 . The Mean Price Target for the Stock by the brokers is at $12.00.

Earnings Estimate & Revenue Estimate of Eleven Biotherapeutics Inc (NASDAQ:EBIO) for the Current Quarter Mar 16:

The Previous Year Earnings per Share (EPS) of this Quarter was $-0.36.

The Trend for 7 days ago was $-0.21. The EPS Trend for 30, 60 and 90 Days ago were $-0.21, $-0.21 and $-0.21 respectively.

The consensus EPS trend allows the investor to understand the recent direction of earnings estimates. The trend shows the investor how the estimates have been changing as new information is published by the company. Trends are usually shown for 90 days, 60 days, 30 days, and 7 days.

If the earnings estimates are declining over time, this is usually a signal that new information made an analyst revise their forecast downward. Generally, an investor wants to see values that remain steady or move in a positive direction.

While looking at Revenue estimate of the company, 1 analysts.

Source – The Street ,  ACAD Charts,  News Oracle
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.

 

See feature articles below:

 

About Broad Street Alerts:

Big opportunities in Small Cap’s

 

Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our members on the last 3 small cap alerts alone!

 

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%

 

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

 

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.

 

These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

Report on: TTNP

SOUTH SAN FRANCISCO, CA — (Marketwired) — 04/15/16 — Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today the presentation of data from the last Phase 3 study of Probuphine®, a six month subdermal buprenorphine implant for the long-term maintenance treatment of opioid addiction, at a poster session during the 47th Annual American Society of Addiction Medicine (ASAM) Annual Conference. The data indicates that participants who were clinically stable on sublingual buprenorphine at a dose of 8mg or less per day maintained stability when transferred to Probuphine, and that they were more likely to sustain abstinence from illicit opioids throughout the six months than participants who remained on sublingual buprenorphine. The Probuphine New Drug Application (NDA) is currently under review by the FDA with an action date of May 27, 2016.

“This was the first head-to-head comparison study of Probuphine and sublingual buprenorphine, demonstrating the efficacy of a long-acting six month buprenorphine implant,” said co-lead investigator and an author of the presentation Richard N. Rosenthal, M.D., Professor of Psychiatry and Medical Director of Addiction Psychiatry at the Icahn School of Medicine at Mount Sinai. “The study results show that participants in the implant group sustained clinical stability over the course of six months. The implant group was also more likely to remain free from illicit opioids at 85.7% compared to 71.9% of those maintained on sublingual buprenorphine. If approved, Probuphine could help expand access to medication to treat opioid use disorders, providing people with a new option.”

The poster titled, “A Randomized Trial of Probuphine Implants in Adults Stabilized on Sublingual Buprenorphine,” presented data from the double-blind, double-dummy study, which was designed to determine the efficacy and safety of Probuphine as a maintenance treatment for opioid addiction. The primary endpoint was a non-inferiority comparison of the Probuphine and the sublingual buprenorphine treatment arms. As previously reported, the study met its primary endpoint as well as all secondary endpoints, and the treatment was well tolerated by the study subjects. Further details are included in the poster presentation, which was co-authored by Michelle R. Lofwall, M.D., University of Kentucky College of Medicine, Center on Drug and Alcohol Research in Lexington, Kentucky; Sonnie Kim, Ph.D., Braeburn Pharmaceuticals; Katherine L. Beebe, Ph.D., Titan Pharmaceuticals; Michael Chen, Ph.D., TCM Groups, Inc.; and Frank J. Vocci, Ph.D., Friends Research Institute.

“We are very pleased to be presenting these important data for the first time at the ASAM meeting and will continue to work closely with our partner, Braeburn Pharmaceuticals, on a broad medical communications strategy for Probuphine, if approved by the FDA,” said Kate Beebe, Ph.D., Executive Vice President and Chief Development Officer of Titan Pharmaceuticals.

Probuphine was developed using Titan’s proprietary platform technology, ProNeura™, a non-biodegradable drug delivery implant designed to provide continuous, long- term steady state levels of medication in the blood. In January 2016, the FDA reviewed the Probuphine NDA at a meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC), and following a discussion of the data presented, the committee voted 12-5 in favor of approval of Probuphine. If approved by the FDA, Probuphine would be the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single procedure.

About the ProNeura Long-term Drug Delivery Platform
ProNeura is Titan’s proprietary, long-term drug delivery platform utilized in the development of products for the treatment of select chronic conditions that may benefit from the delivery of continuous, non-fluctuating levels of certain medications over an extended period of six months to a year. ProNeura consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subdermally, normally in the inner part of the upper arm, during a simple office procedure, and is removed in a similar manner at the end of treatment. The drug substance is released continuously through the process of dissolution, resulting in a stable, non-fluctuating blood level similar to that seen with intravenous administration. These long-term, linear-release characteristics are medically desirable to avoid the peak and trough swings from oral dosing that pose problems in the current treatments for many diseases, especially diseases of the central nervous system. Titan has issued patents as well as patent applications covering the use of the ProNeura long-term drug delivery platform for the formulation of specific products for the treatment of certain chronic diseases, such as opioid addiction, Parkinson’s disease, and others.

About Titan Pharmaceuticals
Titan Pharmaceuticals Inc. (NASDAQ: TTNP), based in South San Francisco, CA, is a specialty pharmaceutical company developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company’s lead product candidate is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan’s proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels of medication for three months or longer. Titan has granted U.S. and Canadian commercial rights for Probuphine to Braeburn Pharmaceuticals. If approved, Probuphine would be the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions, such as Parkinson’s disease, where maintaining consistent blood levels of a therapeutic agent may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.

 

Source – Company Press Release

 

 

Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.

 

Stock market

 

Hot small cap stocks

 

small cap stock picks

 

Biotech stocks

 

FDA approval stocks

 

FDA calendar

 

Trade stocks

 

Become a day trader

 

Day trade stocks for a living

 

PDUFA date set

 

micro cap stocks

 

Best stocks 2016

 

Hottest small cap stocks

 

Best stock picks

 

Who to follow for stock picks

 

Apple news stock picks

 

Stock picks on apple news

 

 

 

 

About Broad Street Alerts:

 

Big opportunities in Small Cap’s in a down market

 

Broadstreetalerts.com recent profiles and track record, 153% in verifiable potential gains for our members in December 2015 alone.

 

 

 

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%

 

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

 

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.

 

 

These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business. We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

 

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

 

 

Due Diligence Report: Low Cost Producer Trying to Make a Move Skywards

Summary:

 

Gold Resource Corporation, incorporated on August 24, 1998, is a producer of metal concentrates that contain gold, silver, copper, lead and zinc, and Dore containing gold and silver at the Aguila Project in the southern state of Oaxaca, Mexico (Oaxaca). The Company has two units in North America, the Oaxaca Mining Unit and the Nevada Mining Unit. The majority of its assets are located at its Oaxaca Mining Unit, located on its Aguila Project, including its Aguila milling facility and Arista underground mine. The Aguila milling facility produces metal concentrates and Dore from ore mined from the Arista mine, which contains precious metal products of gold and silver, and by-products of copper, lead and zinc. The Company’s operations in Oaxaca are conducted through its Mexican subsidiary, Don David Gold Mexico S.A. de C.V. (DDGM). Its Nevada exploration is done through its subsidiary, GRC Nevada Inc.

The Company’s mineral properties are classified into various categories, such as Operating Properties and Exploration Properties. Operating Properties are properties on which the Company operates a producing mine and is considered a material property. The Company has an interest in approximately nine properties, where over six of its properties, including one Operating Property and approximately five Exploration Properties, are in its Oaxaca Mining Unit, which is located in the southern state of Oaxaca, Mexico. The Company has approximately three Exploration Properties within its Nevada Mining Unit located in south central Nevada’s Walker Lane Mineral Belt in the United States.

The properties of Oaxaca Mining Unit are located in Oaxaca, Mexico in what is known as the San Jose structural corridor, which runs north 70 degrees west. Its properties comprise over 55 continuous kilometers of this structural corridor, which spans three mining districts in Oaxaca. Its operating properties include Aguila Project, Margaritas property, Alta Gracia Property, Chamizo Property, Fuego Property and Rey property. The Aguila Project comprises approximately 20 mining concessions aggregating approximately 30,070 hectares. The Margaritas property consists of the La Tehuana concession. The Fuego property consists of approximately 2,554 hectares and is located south of its Alta Gracia and Chamizo properties. The Rey property consists of concessions on the far northwest end of its 55 kilometer mineralized corridor in the State of Oaxaca known as Rey, El Virrey, La Reyna and El Marquez.

 

The Nevada Mining Unit consists of Radar property, Goose property and Gold Mesa. The Radar property covers an area of approximately 3,550 acres and is made up of over 180 unpatented lode claims located in the Walker Lane Mineral Belt in central Nevada. The Goose property consists of five unpatented lode claims covering approximately 100 acres adjacent to Radar in the Walker Lane Mineral Belt. The claims comprising the Goose property cover Newman Ridge, a mountain located directly west of the past producing Paradise Peak mine, near the Round Mountain and Rawhide mines. Gold Mesa consists of approximately 1,780 acres with 89 unpatented claims and 3 patented claims in central Nevada’s Walker Lane Mineral Belt. The property is located 17 miles south-southeast of the Radar and Goose properties.

 

Gold Resource Corporation has a current market capitalization of $179.49 M with 54.27 M outstanding shares. Its daily average volume traded is 0.54 M shares.

Financial Highlights (Q4 2015):

Revenue: 21.62 M

Gross Profit: 4.93 M

Net Income: -2.33 M

Cash and Cash Equivalents: 12.82 M

Total Debt: 0.84 M

Recent News and Analysis:

The company recently reported preliminary production results for the first quarter ended March 31, 2016 of approximately 6,463 ounces of gold, 434,100 ounces of silver and significant base metals during the first quarter. Gold Resource Corporation is a gold and silver producer with operations in Oaxaca, Mexico and exploration in Nevada, USA. The Company has returned $108 million to shareholders in monthly dividends since commercial production commenced July 1, 2010, and offers shareholders the option to convert their cash dividends into physical gold and silver and take delivery.  Preliminary first quarter production at the Company’s Arista mine totaled approximately 6,463 ounces of gold, 434,100 ounces of silver, 244 tonnes of copper, 838 tonnes of lead and 3,261 tonnes of zinc. The Company maintains its 2016 Outlook of 26,000 gold ounces and 1,900,000 silver ounces. Additionally the company declared its monthly instituted dividend of 1/6 of a cent per common share for April 2016 payable on May 23, 2016 to shareholders of record as of May 11, 2016. Gold Resource Corporation is a gold and silver producer with operations in Oaxaca, Mexico and exploration in Nevada, USA.

Conclusions:

To get more leverage for investors who are looking to take advantage of the gold ride, GORO is the most suitable example with a limited downside risk and a huge upside opportunity. GORO is a company with the lowest Equity Value/Sales metrics along with Harmony Resources. However, the latter has lower profit margins with higher debt/capital. GORO is among the lowest producers, with about $600 cash cost/ounce which is one of the lowest cost producers in the world. The problem with GORO is that it depends on only one mine, the Arista Mine. It’s currently exploring about 3 mines in Nevada and Mexico. That is why a strike or inability to find a mine with good producing capacity may be a headwind for this company. With upcoming earnings, and gold price appreciating as it has for the past 4 months, upside can be expected from this junior miner.

Sources:

1. http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=GORO.K
2. http://www.google.ca/finance?q=NYSEMKT%3AGORO&fstype=ii&hl=en&gl=ca&ei=qBYpV-n3LsTijAHCtIiQCw
3. http://finance.yahoo.com/news/gold-corporation-reports-preliminary-first-123000454.html
4. http://finance.yahoo.com/news/gold-corporation-declares-april-monthly-123000292.html
5. http://seekingalpha.com/article/3970019-gold-resource-biggest-gold-opportunity

 

 

 

 

 

Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it, and I have no business relationship with any company whose stock is mentioned in the article. I reserve the right to sell the redistribution rights to this report for up to two hundred fifty dollars/news source.

The information contained herein is not intended to be investment advice and does not constitute any form of invitation or inducement by Robert Borowski, MSc. to engage in investment activity. Neither the information nor any opinion expressed constitutes a solicitation for the purchase or sale of any security. Securities, financial instruments, strategies, or commentary mentioned herein may not be suitable for all investors and this material is not intended for any specific investor and does not take into account an investor’s particular investment objectives, financial situations or needs. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only current as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fluctuate, and an investor may, upon selling an investment lose a portion of, or the entire principal amount invested. Past performance is no guarantee of future results. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

DISCLAIMER

Broad Street Alerts has compensated the author of this report up to two hundred and fifty dollars for the redistribution rights for a period of up to 30 days.

BroadStreetAlerts.com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We have not been compensated in any form by any entity for this report. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.

SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.